RMD - ResMed Stock

Market Summary

USD136.61+0.32

Market Closed

0.23%

RMD Alerts

2 major insider sales recently.

RMD Stock Price

RMD RSI Chart

RMD Valuation

Market Cap

20.1B

Price/Earnings (Trailing)

22.38

Price/Sales (Trailing)

4.76

EV/EBITDA

17.46

Price/Free Cashflow

35.02

RMD Price/Sales (Trailing)

RMD Profitability

EBT Margin

26.47%

Return on Equity

21.94%

Return on Assets

12.85%

Free Cashflow Yield

2.86%

RMD Fundamentals

RMD Revenue

Revenue (TTM)

4.2B

Revenue Y/Y

22.66%

Revenue Q/Q

0.46%

RMD Earnings

Earnings (TTM)

897.6M

Earnings Y/Y

17.74%

Earnings Q/Q

-1.22%

Price Action

52 Week Range

136.22242.42

(Low)(High)

Last 7 days

-6.0%

Last 30 days

-15.7%

Last 90 days

-36.4%

Trailing 12 Months

-35.5%

RMD Financial Health

Current Ratio

3.07

Debt/Equity

0.4

Debt/Cashflow

0.34

RMD Investor Care

Dividend Yield

1.29%

Dividend/Share (TTM)

1.76

Shares Dilution (1Y)

0.45%

Diluted EPS (TTM)

6.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for RMD

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-09-15	Farrell Michael J.	sold	-830,514	146	-5,675	chief executive officer
2023-09-15	Farrell Michael J.	acquired	327,788	57.76	5,675	chief executive officer
2023-09-01	Rider Michael J	sold	-4,028	161	-25.00	global general counsel
2023-08-25	BLAISE LUCILE	sold (taxes)	-62,903	165	-379	president, sleep & rc business
2023-08-17	Sandercock Brett	acquired	-	-	4,972	chief financial officer
2023-08-17	Farrell Michael J.	acquired	-	-	12,430	chief executive officer
2023-08-17	BLAISE LUCILE	acquired	-	-	4,113	president, sleep & rc business
2023-08-17	Ghoshal Kaushik	acquired	-	-	2,486	president, saas business
2023-08-17	Rider Michael J	acquired	-	-	2,247	global general counsel
2023-08-15	Farrell Michael J.	sold	-1,039,650	183	-5,675	chief executive officer

Which funds bought or sold RMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-09-21	Halpern Financial, Inc.	new	-	12,455	12,455	-%
2023-09-21	Jefferies Group LLC	new	-	3,227,570	3,227,570	0.03%
2023-09-20	BARCLAYS PLC	added	157	53,053,000	86,847,000	0.06%
2023-09-12	Farther Finance Advisors, LLC	added	2.78	803	32,338	0.01%
2023-09-07	ST GERMAIN D J CO INC	new	-	4,910,790	4,910,790	0.26%
2023-09-05	Covenant Partners, LLC	unchanged	-	-2,287	1,020,180	0.37%
2023-09-01	Portside Wealth Group, LLC	new	-	321,422	321,422	0.06%
2023-08-28	Lavaca Capital LLC	unchanged	-	-1,423	634,743	0.19%
2023-08-24	Alberta Investment Management Corp	added	2.66	18,606	785,071	0.01%
2023-08-22	COMERICA BANK	new	-	9,000	9,000	-%

Latest Funds Activity

Are funds buying RMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RMD

No. of Funds

RMD Alerts

2 major insider sales recently.

Schedule 13G FIlings of ResMed

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 10, 2023	wcm investment management, llc	2.6%	3,832,642	SC 13G/A
Feb 09, 2023	vanguard group inc	11.63%	17,028,881	SC 13G/A
Feb 07, 2023	blackrock inc.	9.4%	13,774,787	SC 13G/A
Feb 10, 2022	vanguard group inc	11.06%	16,119,963	SC 13G/A
Feb 10, 2022	wcm investment management, llc	6.21%	9,046,150	SC 13G/A
Feb 01, 2022	blackrock inc.	9.3%	13,561,224	SC 13G/A
Feb 10, 2021	wcm investment management, llc	6.09%	8,821,570	SC 13G/A
Feb 10, 2021	vanguard group inc	10.65%	15,439,844	SC 13G/A
Feb 01, 2021	blackrock inc.	9.7%	14,073,568	SC 13G/A
Feb 12, 2020	vanguard group inc	10.98%	15,790,293	SC 13G/A

Recent SEC filings of ResMed

View All Filings

Date Filed	Form Type	Document
Sep 19, 2023	4	Insider Trading
Sep 15, 2023	144	Notice of Insider Sale Intent
Sep 07, 2023	4	Insider Trading
Sep 01, 2023	144	Notice of Insider Sale Intent
Aug 29, 2023	4	Insider Trading
Aug 18, 2023	4	Insider Trading
Aug 18, 2023	4	Insider Trading
Aug 18, 2023	4	Insider Trading
Aug 18, 2023	4	Insider Trading
Aug 18, 2023	4	Insider Trading

Peers (Alternatives to ResMed)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
SYK	108.3B	19.5B	3.38%	36.58%	39.99	5.57	10.36%	30.30%
ISRG	101.2B	6.7B	-0.75%	50.83%	71.05	15.19	11.75%	-0.66%
BSX	77.5B	13.4B	6.45%	36.39%	85	5.78	8.69%	3.17%
BDX	71.3B	19.0B	-4.29%	12.66%	44.09	3.79	0.46%	-5.24%
EW	42.3B	5.7B	-8.22%	-17.24%	30.48	7.49	5.64%	-4.53%
MID-CAP
PEN	9.5B	937.8M	-2.12%	37.22%	325.65	10.11	16.30%	250.21%
SWAV	7.1B	616.6M	-12.54%	-24.86%	29.24	11.56	69.52%	343.68%
GMED	5.1B	1.1B	-6.10%	-12.07%	24.23	4.65	12.63%	50.85%
IRTC	2.6B	452.1M	-21.20%	-33.94%	-26.32	5.78	24.99%	24.09%
TNDM	1.3B	790.3M	-27.09%	-56.49%	-5.97	1.69	3.21%	-1604.53%
SMALL-CAP
ATEC	1.6B	421.8M	-15.15%	56.11%	-9.32	3.69	44.49%	-2.43%
AVNS	947.4M	780.7M	-7.75%	-9.65%	-26.32	1.21	4.68%	-510.17%
CSII	839.3M	239.8M	0.70%	0.15%	-22.16	3.5	-4.74%	-31.15%
SILK	609.7M	162.9M	-27.67%	-61.65%	-11.53	3.74	42.67%	12.82%

ResMed News

Returns for RMD

Cumulative Returns on RMD

11.6%

10-Year Cumulative Returns

12.9%

7-Year Cumulative Returns

4.7%

5-Year Cumulative Returns

-6.7%

3-Year Cumulative Returns

Risks for RMD

What is the probability of a big loss on RMD?

66.2%

Probability that ResMed stock will be more than 20% underwater in next one year

29.2%

Probability that ResMed stock will be more than 30% underwater in next one year.

0.4%

Probability that ResMed stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RMD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ResMed was unfortunately bought at previous high price.

Drawdowns

Financials for ResMed

Income Statement (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	5.2%	4,223	4,016	3,763	3,624	3,578	3,539	3,444	3,349	3,197	3,091	3,092	3,028	2,957	2,892	2,784	2,699	2,607	2,525	2,455	2,405	2,340
Gross Profit	4.2%	2,356	2,261	2,134	2,059	2,024	1,993	1,949	1,907	1,839	1,798	1,800	1,765	1,718	1,671	1,602	1,550	1,494	1,434	1,397	1,372	1,335
Operating Expenses	6.5%	1,224	1,149	1,089	1,045	1,024	1,006	973	958	935	912	921	909	908	963	955	943	915	829	813	799	793
S&GA Expenses	5.7%	874	827	781	755	738	726	704	688	670	654	666	668	677	683	675	665	645	630	614	604	600
R&D Expenses	5.0%	288	274	264	257	254	249	238	231	225	218	213	208	202	201	197	190	181	169	159	157	155
EBITDA	-100.0%	-	1,181	1,125	1,074	1,098	1,095	1,085	1,058	1,017	1,043	1,020	991	928	819	771	-	-	-	-	-	-
EBITDA Margin	-100.0%	-	0.29*	0.30*	0.30*	0.31*	0.31*	0.31*	0.32*	0.32*	0.34*	0.33*	0.33*	0.31*	0.28*	0.28*	-	-	-	-	-	-
Interest Expenses	-24.8%	-47.38	-37.98	-28.48	-24.09	-22.31	-58.74	-47.45	-35.71	-23.63	-52.20	-48.05	-43.62	-39.36	44.00	46.00	43.00	36.00	29.00	24.00	24.00	28.00
Earnings Before Taxes	3.6%	1,102	1,063	1,000	963	960	962	953	927	884	857	830	798	733	617	563	512	519	557	-	552	521
EBT Margin	-100.0%	-	0.26*	0.27*	0.27*	0.27*	0.27*	0.28*	0.28*	0.28*	0.28*	0.27*	0.26*	0.25*	0.21*	0.20*	-	-	-	-	-	-
Net Income	4.0%	898	863	809	786	779	779	522	500	475	457	699	680	622	513	455	419	405	446	450	335	316
Net Income Margin	-100.0%	-	0.21*	0.22*	0.22*	0.22*	0.22*	0.15*	0.15*	0.15*	0.15*	0.23*	0.22*	0.21*	0.18*	0.16*	-	-	-	-	-	-
Free Cashflow	-100.0%	-	421	237	325	216	364	465	411	634	748	788	698	707	514	429	-	-	-	-	-	-

Balance Sheet
(In Millions)

Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Assets	0.6%	6,752	6,714	6,676	5,178	5,096	4,905	4,735	4,729	4,728	4,586	4,573	4,621	4,587	4,511	4,354	4,155	4,108	4,099	3,860	3,068	3,064
Current Assets	1.3%	2,368	2,338	2,325	2,034	1,931	1,704	1,547	1,586	1,575	1,466	1,451	1,543	1,523	1,470	1,300	1,161	1,145	1,103	1,064	1,088	1,066
Cash Equivalents	0.0%	228	228	253	207	274	202	194	276	295	231	256	421	463	353	204	172	147	147	149	230	189
Inventory	-1.3%	998	1,011	989	865	744	665	592	507	457	484	475	478	417	359	378	357	350	320	297	283	269
Net PPE	1.7%	538	529	523	487	498	513	478	467	463	455	459	425	417	397	408	383	387	382	382	382	387
Goodwill	-0.5%	2,770	2,784	2,767	1,939	1,936	1,946	1,951	1,922	1,928	1,926	1,910	1,900	1,890	1,884	1,871	1,856	1,856	1,939	1,759	1,192	1,069
Liabilities	-5.7%	2,622	2,781	2,938	1,745	1,735	1,626	1,589	1,703	1,842	1,876	1,708	1,942	2,090	2,254	2,096	2,037	2,035	2,077	1,904	1,167	1,005
Current Liabilities	-0.4%	759	762	733	693	689	667	621	624	912	877	577	591	603	552	500	550	556	463	436	421	511
Short Term Borrowings	0.0%	10.00	10.00	10.00	10.00	10.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	11.00
Long Term Debt	-9.2%	1,431	1,576	1,791	785	765	669	668	794	643	719	814	1,044	1,164	1,365	1,288	1,208	1,259	1,323	1,186	518	270
Shareholder's Equity	5.0%	4,130	3,933	3,738	3,433	3,361	3,279	3,146	3,026	2,886	2,709	2,865	2,679	2,497	2,256	2,258	2,117	2,072	2,021	1,956	1,900	2,059
Retained Earnings	4.0%	4,253	4,088	3,920	3,760	3,614	3,480	3,363	3,222	3,080	2,941	3,077	2,954	2,833	2,712	2,605	2,501	2,436	2,421	2,368	2,296	2,432
Additional Paid-In Capital	2.5%	1,772	1,729	1,711	1,702	1,682	1,645	1,629	1,644	1,622	1,587	1,574	1,588	1,571	1,534	1,522	1,530	1,511	1,476	1,461	1,464	1,451
Shares Outstanding	0.1%	147	147	147	146	146	146	146	146	146	146	145	145	145	145	144	144	144	143	143	143	143

Cashflow (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	29.5%	693	535	370	461	351	498	577	527	737	840	884	784	802	614	514	573	459	447	456	459	505
Share Based Compensation	5.9%	71.00	67.00	65.00	65.00	65.00	66.00	66.00	65.00	64.00	63.00	62.00	60.00	58.00	56.00	54.00	53.00	52.00	50.00	49.00	49.00	48.00
Cashflow From Investing	0.7%	-1,159	-1,168	-1,189	-246	-229	-222	-231	-178	-158	-113	-154	-168	-179	-220	-346	-960	-1,075	-1,070	-864	-234	-101
Cashflow From Financing	-36.8%	423	669	888	-263	-128	-299	-397	-496	-764	-886	-710	-392	-317	-178	-113	336	581	90.00	-270	-775	-1,026
Dividend Payments	1.3%	258	255	252	249	245	241	236	231	227	226	226	226	225	222	218	215	212	209	206	203	199
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23.00	49.00	68.00	86.00	54.00

RMD Income Statement

2023-06-30

Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Net revenue	$ 4,222,993	$ 3,578,127	$ 3,196,825
Cost of sales (exclusive of amortization shown separately below)	1,836,935	1,514,166	1,312,598
Amortization of acquired intangible assets	30,396	39,650	45,127
Total cost of sales	1,867,331	1,553,816	1,357,725
Gross profit	2,355,662	2,024,311	1,839,100
Operating Expenses [Abstract]
Selling, general, and administrative	874,003	737,508	670,387
Research and development	287,642	253,575	225,284
Amortization of acquired intangible assets	42,020	31,078	31,078
Restructuring expenses (note 18)	9,177	0	8,673
Acquisition related expenses	10,949	1,864	0
Total operating expenses	1,223,791	1,024,025	935,422
Income from operations	1,131,871	1,000,286	903,678
Other income (loss), net:
Interest (expense) income, net	(47,379)	(22,312)	(23,627)
Loss attributable to equity method investments (note 5)	(7,265)	(8,486)	(11,205)
Gain (loss) on equity investments (note 5)	9,922	(12,202)	14,515
Gain on insurance recoveries	20,227	0	0
Other, net	(5,712)	3,197	301
Total other income (loss), net	(30,207)	(39,803)	(20,016)
Income before income taxes	1,101,664	960,483	883,662
Income taxes (note 12)	204,108	181,046	409,157
Net income	$ 897,556	$ 779,437	$ 474,505
Basic earnings per share (note 11) (in dollars per share)	$ 6.12	$ 5.34	$ 3.27
Diluted earnings per share (note 11) (in dollars per share)	6.09	5.30	3.24
Dividend declared per share (in dollars per share)	$ 1.76	$ 1.68	$ 1.56
Basic shares outstanding (000's) (in shares)	146,765	146,066	145,313
Diluted shares outstanding (000's) (in shares)	147,455	147,043	146,451
Sleep and Respiratory Care products
Net revenue	$ 3,725,017	$ 3,177,298	$ 2,823,235
Cost of sales (exclusive of amortization shown separately below)	1,662,957	1,365,421	1,177,309
Amortization of acquired intangible assets	5,340	4,105	4,895
Software as a Service
Net revenue	497,976	400,829	373,590
Cost of sales (exclusive of amortization shown separately below)	173,978	148,745	135,289
Amortization of acquired intangible assets	$ 25,056	$ 35,545	$ 40,232

RMD Balance Sheet

2023-06-30

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Current assets:
Cash and cash equivalents	$ 227,891	$ 273,710
Accounts receivable, net of allowances of $23,603 and $23,259 ‎at June 30, 2023 and June 30, 2022, respectively	704,909	575,950
Inventories (note 3)	998,012	743,910
Prepaid expenses and other current assets (note 3)	437,018	337,908
Total current assets	2,367,830	1,931,478
Non-current assets:
Property, plant and equipment, net (note 3)	537,856	498,181
Operating lease right-of-use assets (note 9)	127,955	132,314
Goodwill (note 4)	2,770,299	1,936,442
Other intangible assets, net (note 4)	552,341	345,944
Deferred income taxes (note 12)	132,974	79,746
Prepaid taxes and other non-current assets	262,453	171,748
Total non-current assets	4,383,878	3,164,375
Total assets	6,751,708	5,095,853
Current liabilities:
Accounts payable	150,756	159,245
Accrued expenses (note 6)	365,660	344,722
Operating lease liabilities, current (note 9)	21,919	21,856
Deferred revenue	138,072	108,667
Income taxes payable (note 12)	72,224	44,893
Short-term debt, net (note 8)	9,902	9,916
Total current liabilities	758,533	689,299
Non-current liabilities:
Deferred revenue	119,186	95,455
Deferred income taxes (note 12)	90,650	9,714
Operating lease liabilities, non-current (note 9)	116,853	120,453
Other long-term liabilities	68,166	5,974
Long-term debt, net (note 8)	1,431,234	765,325
Long-term income taxes payable (note 12)	37,183	48,882
Total non-current liabilities	1,863,272	1,045,803
Total liabilities	2,621,805	1,735,102
Commitments and contingencies (note 15)
Stockholders’ equity:
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued	0	0
Common stock, $0.004 par value, 350,000,000 shares authorized; ‎188,900,583 issued and 147,064,349 outstanding at June 30, 2023 and ‎188,246,955 issued and 146,410,721 outstanding at June 30, 2022	588	586
Additional paid-in capital	1,772,083	1,682,432
Retained earnings	4,253,016	3,613,736
Treasury stock, at cost, 41,836,234 shares at June 30, 2023 and June 30, 2022	(1,623,256)	(1,623,256)
Accumulated other comprehensive loss	(272,528)	(312,747)
Total stockholders’ equity	4,129,903	3,360,751
Total liabilities and stockholders’ equity	$ 6,751,708	$ 5,095,853

ResMed Inc Stock Research

Market Summary

RMD Alerts

RMD Stock Price

RMD RSI Chart

RMD Valuation

RMD Price/Sales (Trailing)

RMD Profitability

RMD Fundamentals

RMD Revenue

RMD Earnings

Price Action

52 Week Range

RMD Financial Health

RMD Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for RMD

Which funds bought or sold RMD recently?

Latest Funds Activity

RMD Alerts

Schedule 13G FIlings of ResMed

Recent SEC filings of ResMed

Peers (Alternatives to ResMed)

ResMed News

Returns for RMD

Cumulative Returns on RMD

Risks for RMD

What is the probability of a big loss on RMD?

How does RMD drawdown profile look like?

Financials for ResMed

Income Statement (Last 12 Months)
(In Millions)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)

RMD Income Statement

RMD Balance Sheet

About ResMed

Market Summary

RMD Alerts

RMD Stock Price

RMD RSI Chart

RMD Valuation

RMD Price/Sales (Trailing)

RMD Profitability

RMD Fundamentals

RMD Revenue

RMD Earnings

Price Action

52 Week Range

RMD Financial Health

RMD Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for RMD

Which funds bought or sold RMD recently?

Latest Funds Activity

RMD Alerts

Schedule 13G FIlings of ResMed

Recent SEC filings of ResMed

Peers (Alternatives to ResMed)

ResMed News

Returns for RMD

Cumulative Returns on RMD

Risks for RMD

What is the probability of a big loss on RMD?

How does RMD drawdown profile look like?

Financials for ResMed

Income Statement (Last 12 Months).css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Balance Sheet(In Millions)

Cashflow (Last 12 Months)(In Millions)

RMD Income Statement

RMD Balance Sheet

About ResMed

Income Statement (Last 12 Months)
(In Millions)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)